Delivery Order SPE2DR25D9214-SPE2DR26FQST5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,746.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a $27,331.66 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on November 4, 2025, with an ultimate completion date of November 26, 2025, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award falls...
- The Defense Logistics Agency awarded a $30.5K firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on November 14, 2025, with an ultimate completion date of December 8, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued...
- The Defense Logistics Agency awarded a delivery order valued at $24,084.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 19, 2025, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a $17,746.12 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract, with an ultimate completion date of November 19, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $36,229.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract is firm fixed-price with an ultimate completion date of October 16, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,289.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on September 12, 2025. The delivery order covers Prolastin C (1,000 mg/20 ml vials), a therapeutic pharmaceutical product, with an ultimate completion date of October 3, 2025. This award utilizes a firm fixed-price contract type with no set-aside designation, allowing DMS Pharmaceutical Group to...
- The Defense Logistics Agency awarded a delivery order valued at $36,122.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contractual relationship with the...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,132.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries an ultimate completion date of September 30, 2025, and was awarded on September 9, 2025, with no set-aside designation applied. DMS Pharmaceutical Group will perform the work at its Park Ridge facility, delivering...
- The Defense Logistics Agency awarded a delivery order valued at $35,824.80 to DMS Pharmaceutical Group Inc. on June 16, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, represents a specific pharmaceutical fulfillment under DMS Pharmaceutical Group's broader contract vehicle with DLA. The award carries no set-aside designation, allowing the woman-owned small business to compete on an unrestricted...
- SPE2DR25D9214Indefinite Delivery Contract
- SPE2DR25D9214-SPE2DR26FQST5Delivery Order
The Defense Logistics Agency awarded a $36,160.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on November 12, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group serves as a critical regional prime vendor contractor within the PPV-G GEN V framework, which authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables. The company's parent indefinite delivery contract, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, with a completion date of December 31, 2036, and includes a 30-month base period with three 30-month option periods. The contractor's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.2k | 11/12/25 |